References:
1. Poddubnyy D, Rudwaleit M. Early spondyloarthritis. Rheum Dis Clin
North Am. mai 2012;38(2):387‑403.
2. Samia B, Hazgui F, Abdelghani KB, Hamida FB, Goucha R, Hedri H, et
al. Atteinte rénale au cours de la spondylarthrite ankylosante.
Néphrologie Thérapeutique. 1 juill 2012;8(4):220‑5.
3. Lee S-H, Lee EJ, Chung SW, Song R, Moon J-Y, Lee S-H, et al. Renal
involvement in ankylosing spondylitis: prevalence, pathology, response
to TNF-a blocker. Rheumatol Int. juill 2013;33(7):1689‑92.
4. Rudwaleit M, Landewé R, van der Heijde D, Listing J, Brandt J, Braun
J, et al. The development of Assessment of SpondyloArthritis
international Society classification criteria for axial
spondyloarthritis (part I): classification of paper patients by expert
opinion including uncertainty appraisal. Ann Rheum Dis. juin
2009;68(6):770‑6.
5. Strobel ES, Fritschka E. Renal diseases in ankylosing spondylitis:
review of the literature illustrated by case reports. Clin Rheumatol.
1998;17(6):524‑30.
6. Ben Taarit C, Ajlani H, Ben Moussa F, Ben Abdallah T, Ben Maïz H,
Khedher A. Les manifestations rénales de la spondylarthrite
ankylosante : à propos de 210 cas. Rev Médecine Interne. 1 déc
2005;26(12):966‑9.
7. Cadiñanos J, Costa R, Trujillo D, Real de Asúa D. [Systemic
secondary AA amyloidosis]. Med Clin (Barc). 1 avr 2015;144(7):324‑30.
8. Shu KH, Lian JD, Yang YF, Lu Y, Wang JY, Lan JL, Chou G.
Glomerulonephritis in ankylosing spondylitis. Clin Nephrol 1986;25:
169–71.
9. Swaak AJG, Frankfort I, Menon RS, Planten O, Pekelharing JM. Absence
of IgA nephropathy in patients with ankylosing spondylitis. Rheumatol
Int 1986;6:145–9.
10. Steisson K, Hirszel P, Weinstein A. Mesangial IgM nephropathy in a
patient with HLA-B27 spondylarthropathy. Arthritis Rheum 1983;26: 1056.
11. Strobel ES, Fritschka E. Renal diseases in ankylosing spondylitis:
review of the literature illustrated by case reports. Clin Rheumatol.
1998;17(6):524‑30.
12. Frikha F, Kaddour N, Frigui M, Jallouli M, Marzouk S, Meftah S, et
al. L’atteinte rénale au cours de la spondylarthrite ankylosante. Rev
Rhum. 1 nov 2006;73(10):1251.
13. Jones DW, Mansell MA, Samuell CT, Isenberg DA. Renal abnormalities
in ankylosing spondylitis. Br J Rheumatol. oct 1987;26(5):341‑5.
14. Paueksakon P, Fogo AB. Drug-induced nephropathies. Histopathology.
2017;70(1):94-108.
15. Artinano M, Etheridge WB, Stroehlein KB, Barcenas CG. Progression of
minimal-change glomerulopathy to focal glomerulosclerosis in a patient
with fenoprofen nephropathy. Am J Nephrol. 1986;6(5):353-7.
16. Andrews PA, Sampson SA. Topical non-steroidal drugs are systemically
absorbed and may cause renal disease. Nephrol Dial Transplant.
1999;14(1):187-9.
17. Markowitz GS, Bomback AS, Perazella MA. Drug-induced glomerular
disease: direct cellular injury. Clin J Am Soc Nephrol.
2015;10(7):1291-9.
18. Lapadula G, Marchesoni A, Armuzzi A, Blandizzi C, Caporali R,
Chimenti S, et al. Adalimumab in the Treatment of Immune-Mediated
Diseases. Int J Immunopathol Pharmacol. janv 2014;27(1_suppl):33‑48.
19. Trachtman H, Vento S, Herreshoff E, Radeva M, Gassman J, Stein DT,
et al. Efficacy of galactose and adalimumab in patients with resistant
focal segmental glomerulosclerosis: report of the font clinical trial
group. BMC Nephrol. 22 juill 2015;16:111.
20. Liu Y, Shi Y, Ren R, Xie J, Wang W, Chen N. Advanced therapeutics in
focal and segmental glomerulosclerosis: Advanced therapeutics in FSGS.
Nephrology. oct 2018;23:57‑61.